
    
      Screening will be performed within 28 days of dosing. Following the single dose of study
      medication, the study period for each patient will be 84 Â± 7 days up to the end-of-study
      visit.

      Total duration for one patient will be up to 17 weeks (up to the end-of-study visit), not
      including the long term observational safety follow-up by phone call for 12 additional weeks.
    
  